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Inﬂammation, University of Glasgow, Glasgow, UKA B S T R A C TObjectives: Cost-effectiveness analyses of technologies for patients
with ankylosing spondylitis frequently require estimates of health
utilities as a function of the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Func-
tional Index (BASFI). Methods: Linear regression, bespoke mixture
models, and generalized ordered probit models were used to model
the EuroQol ﬁve-dimensional questionnaire as a function of BASDAI
and BASFI. Data were drawn from a large UK cohort study (n ¼ 516
with up to ﬁve observations) spanning the full range of disease
severity. Results: Linear regression was systematically biased. Three-
and four-component mixture models and generalized probit models
exhibit no such bias and improved ﬁt to the data. The mean, median,
mean error, and mean absolute error favored the mixture model
approach. Root mean square error favored the generalized orderedee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
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.probit model approach for the data as a whole. Model ﬁt assessed
using these same measures by disease severity quartiles tended to be
best using the mixture models. The value of moving from good to poor
health may differ substantially according to the chosen method.
Simulated data from the mixture and probit models yield a very
similar distribution to the original data set. Conclusions: These
results add to a body of evidence that the statistical model used to
estimate health utilities matters. Linear models are not appropriate.
The four-class bespoke mixture model approach provides the best
performing method to estimate the EuroQol ﬁve-dimensional ques-
tionnaire values from BASDAI and BASFI.
Keywords: ankylosing spondylitis, EQ-5D, mapping.
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A substantial proportion of economic evaluations estimate the
incremental cost per quality-adjusted life-year from studies of
clinical effectiveness in which no utility-based instrument was
administered [1]. They span a broad range of disease areas. Many
studies bridge the gap between clinical outcomes measured
within a trial and utility-based measures required to calculate
quality-adjusted life-years using regression-based methods.
This entails the use of a separate, external data set in which
some samples of patients have data recorded simultaneously for
both the relevant clinical outcome measure(s) and the desired
preference-based measure. A regression can then be con-
structed with the preference-based measure as the dependent
variable and the clinical outcome measures(s) and other cova-
riates as independent variables and the results used to estimate
values required in the economic evaluation. The term “map-
ping” has been used by health economists to describe this
process.Ankylosing spondylitis (AS) is one disease area in which such
methods have been widely applied. AS is an inﬂammatory
disease principally affecting the sacroiliac joints at the base of
the spine and the spine itself, causing back pain, stiffness, and
risk of spinal fracture in later stages of the disease [2–4]. There
may be the development of new bone and joint ﬁxation, termed
ankylosis. Other large joints may be affected and less commonly
the eyes, the bowel, and the cardiovascular system. Symptom
onset is typically in late teens or early adult years, with males
affected two to three times more commonly than females. The
spinal disease is generally progressive and irreversible.
Therapies for AS include drugs used as disease modiﬁers in
rheumatoid arthritis and nonsteroidal anti-inﬂammatory drugs.
Physiotherapy and exercise aim to provide symptomatic relief
and spinal mobility improvement. In recent years, biologic drugs
such as etanercept and adalimumab have been licensed for use
in AS. These are high-cost therapies, obvious candidates for
economic evaluation, and consequently feature in most pub-
lished cost-effectiveness studies.on behalf of International Society for Pharmacoeconomics and
lated Research, University of Shefﬁeld, Regent Court, 30 Regent
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DAI) is the most commonly used instrument to measure disease
activity in AS [5]. It comprises six patient-reported questions
relating to ﬁve major symptoms: fatigue, axial pain, peripheral
pain, stiffness, and enthesopathy. Responses are recorded on a
10-cm visual analogue scale or an 11-point numerical rating
scale, with higher scores indicating higher disease activity.
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a
measure of physical function [6]. It is a patient-assessed, vali-
dated, composite index made up of 10 questions that address
function and the patient’s ability to manage his or her AS. As
with the BASDAI, responses are recorded on a 10-cm visual
analogue scale or an 11-point numerical rating scale. The BASFI
is scored on a 0 to 100 scale, with higher scores indicating a
greater degree of functional impairment. These scores are widely
applied in clinical practice and studies [7].
Mapping functions that feature in cost-effectiveness studies
in AS are all simple linear regressions to estimate the values of
Health Utilities Index Mark 3 [8] or the EuroQol ﬁve-dimensional
questionnaire (EQ-5D) [9–12]. Yet, it is now well established that
linear regression models tend to lead to biased results because of
several characteristics inherent to health utility instruments.
Speciﬁcally, utility instruments have upper and lower bounds,
have a mass at the upper bound, and can be further characterized
by multimodality and skewness. Most statistical models that
have been applied in the mapping ﬁeld, and linear models in
particular, systematically underestimate health utilities for those
in relatively good health and overestimate utilities for those in
poor health, thus underestimating the cost-effectiveness of
health technologies. Kobelt et al. [13] recognized that simple
regression models are inappropriate and instead simply calcu-
lated mean EQ-5D values for each of 25 different BASDAI/BASFI-
deﬁned categories for use in their evaluation of inﬂiximab. These
features have been demonstrated in diverse disease areas such as
cancer [14], heart disease [15], and incontinence [16] as well as in
other rheumatological conditions such as rheumatoid arthritis
[17–19] and osteoarthritis [20].
There is therefore a need to generate appropriate functions to
link BASDAI and BASFI to health utilities to produce unbiased
estimates of cost-effectiveness. This article addresses that need
by estimating the UK tariff EQ-5D using data from a large UK
cohort study. Statistical models estimated are those that have
both theoretical and empirical evidence to support their appro-
priateness in modeling EQ-5D. These are 1) a direct modeling
approach based on mixture models comprising distributions
bespoke to the EQ-5D and 2) an indirect approach that estimates
the probability of being at each of the three levels of the ﬁve EQ-
5D dimensions followed by calculation of the expected tariff
value. These approaches have been compared directly using data
from patients with rheumatoid arthritis, linking the Heath
Assessment Questionnaire instrument to the EQ-5D [17]. In that
setting, both methods overcame the problem of systematic bias
and demonstrated performance superior to that of the linear
model, with the direct approach achieving better outcomes than
the indirect approach. This article aims to provide further com-
parative evidence of mapping method performance.Methods
Primary Data Set
Five hundred sixteen patients with AS provided data on up to ﬁve
occasions to the Population-Based Ankylosing Spondylitis cohort
study in Wales, UK. For a full description of the study, see
Atkinson et al. [21]. In brief, these patients were recruited by
sending letters to patients registered as having AS withrheumatologists in Wales, as well as patients registered with
participating family doctors. Participants had to have a diagnosis
of AS conﬁrmed by a rheumatologist. Participants completed
questionnaires, either online or via a paper-based postal method,
every 3 months, including demographic data, measures of
severity, work and activity limitations, out-of-pocket expenses,
transport to health care appointments and carer assistance,
ﬂares, exercise, and coping questions. The study had ethical
approval from the London Multi-centre Research Ethics Commit-
tee (Research Ethics committee no. 08/H0718/64), and the written
consent of participants was obtained according to the Declaration
of Helsinki.
Statistical Methods
The distribution of the EQ-5D exhibits many features that render
standard approaches to regression analysis inappropriate. The
EQ-5D tariff score is bounded at 1 (full health) and exhibits a large
gap to the next feasible value of 0.883. There is a lower bound of
0.594, and the remainder of the distribution tends to be bimodal
or trimodal. Although the linear regression model is the most
widely applied in this ﬁeld, it has been repeatedly shown to
predict values outside the feasible range, to underpredict EQ-5D
scores for patients in relatively good health and overpredict EQ-
5D scores for patients in severe health states.
In this article, we tested methods that have theoretical
relevance for these type of data and have some degree of
empirical support in the literature, namely, the direct approach
based on bespoke mixture modeling ﬁrst reported in Hernandez
Alava et al. [19] and the indirect approach based on generalized
ordered probit models reported in Hernandez Alava et al. [17]. Full
details of these statistical models can be found elsewhere [17,19].
We included linear regression for comparative purposes.
The direct approach uses mixture models because of their
ﬂexibility to approximate complex nonstandard distributions as a
mixture of component distributions. For the EQ-5D, the compo-
nent distributions are limited above and below at the appropriate
level for the UK tariff, and also have a gap between 1 and 0.883 to
mirror feasible values in the tariff. The modeling approach is
therefore appropriate for the EQ-5D whether it is intended to use
results in a cohort or individual simulation-based economic
assessment.
The indirect approach is a development of “response map-
ping” described by Gray et al. [22] but that respects the ordered
nature of the responses. Five separate generalized ordered probit
models are estimated where the dependent variable is the level
(“no problems,” “some problems,” and “no problems”) for each of
the ﬁve dimensions of health described by the EQ-5D. This stage
leads to estimates of the probability of being at each of these three
levels. The probability of being in any of the 243 health states
described by the EQ-5D can then be calculated conditional on
covariates. The expected tariff is then calculated analytically [17].
All analyses were calculated using STATA v13. The indirect
method was analyzed using the GOPROBIT command. Previous
applications of the direct mixture model approach have used the
GAUSS software. For this application, we programmed a new
STATA command, ALDVMM.ado, which implements a version of
the bespoke mixture model for independent observations and is
available as an Appendix in this article’s Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.02.016. Models were
estimated using maximum likelihood. Reported P-values are
based on robust standard errors to take into account the repeated
observations.
We considered BASDAI, BASFI, age, sex, and disease duration
as potential covariates. Alternative models were compared in
terms of Akaike and Bayesian information criteria. The overall
mean estimates, mean absolute error, and root mean square
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analysts may wish to use these models to simulate actual EQ-
5D data, rather than expected EQ-5D values conditional on
covariates, we also compare the simulated data for each model
with the original data set.Results
Characteristics of the sample are presented in Table 1. Patients
have a mean age of 54 years and mean age at diagnosis of 33
years. BASDAI, BASFI (both reported on a 0–100 scale), and the
EQ-5D span the entire severity of feasible disease states. AS is
approximately thrice more common in men than in women, a
fact reﬂected in this sample.
The optimal linear model identiﬁed included age, BASDAI/100-
squared, BASFI/100, and BASFI/100-squared as explanatory varia-
bles. Models including disease duration as a covariate did not
perform as well. Coefﬁcient values are provided in Appendix
Table 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.02.016. This shows that the EQ-5D value decreases
at an increasing rate when either BASFI or BASDAI increases.
Increasing age leads to a small, though statistically signiﬁcant,
increase in the EQ-5D value. BASDAI/100, BASFI/100, and age were
identiﬁed as the optimal variables to include in the ﬁve general-
ized ordered probit models in the indirect modeling approach. We
included the same explanatory variables in all the ﬁve models
even though they were not universally statistically signiﬁcant.
Results are presented in Appendix Table 2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.02.016. Coef-
ﬁcients are difﬁcult to interpret directly even in terms of directionTable 1 – Characteristics of the sample.
Variable N
Age (y) 1615 5
Age at diagnosis (y) 1581 3
BASDAI 1615 4
BASFI 1615 4
EQ-5D 1615
Sex: male 1231
EQ-5D Mobility
No problems 661
Some problems 953
Conﬁned to bed 2
EQ-5D Self-Care
No problems 1039
Some problems 558
Unable to wash or dress 19
EQ-5D Usual Activities
No problems 533
Some problems 982
Unable to perform 101
EQ-5D Pain
No pain or discomfort 223
Moderate pain or discomfort 1130
Extreme pain or discomfort 263
EQ-5D Anxiety and Depression
Not anxious or depressed 911
Moderately anxious or depressed 641
Extremely anxious or depressed 64
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, B
dimensional questionnaire.of effect. BASDAI has a positive coefﬁcient for both levels 1 and 2
for the EQ-5D dimensions of “usual activities,” “pain,” and “anxiety
and depression.” This means that as BASDAI increases, the
probability of being at level 1 (“no problems”) of the EQ-5D domain
decreases and the probability of being at level 3 (“severe prob-
lems”) increases. For BASFI, this is the case for all ﬁve dimensions.
We compared different number of components for the mix-
ture models and selected three and four classes as the best
performing ones that maintained generalizability. Both models
include age, BASDAI/100, and BASFI/100 within the components
and also BASDAI/100 and BASFI/100 as predictors of component
membership. The three-component model has each element
centered approximately on EQ-5D scores of 0.6, 0.65, and 0.2.
The four-component model has component mean EQ-5D scores
of 0.92, 0.76, 0.22, and 0.54. In all cases, there is a negative
relationship between BASFI/BASDAI and the EQ-5D, except in
component 2 for which there is a positive estimated coefﬁcient
for BASDAI. This is the component centered on the highest levels
of the EQ-5D, where it may be the case that function rather than
disease activity is more relevant. It should also be noted that the
overall expected impact of changes in BASDAI is made up of the
weighted average from the different components, which retains
the expected negative relationship with the EQ-5D. Estimated
parameter values for these two models are provided in Appendix
Table 3 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.02.016.
Comparisons of summary measures of ﬁt are presented in
Table 2. For the overall sample, estimates from the three- and
four-class direct mixture model approach are extremely similar
to each other in most dimensions. The four-class model slightly
outperforms the three-class model and is the optimal of allMean  SD Minimum Maximum
4.42  13.44 19.64 99.89
3.62  12.59 10 90
2.71  24.55 0 100
7.73  28.74 0 100
0.58  0.31 0.594 1
%
76.51
40.9
58.97
0.12
64.29
34.53
1.18
32.98
60.77
6.25
13.8
69.93
16.27
56.37
39.67
3.96
ath Ankylosing Spondylitis Functional Index; EQ-5D, EuroQol ﬁve-
Table 2 – Summary measures of ﬁt for full sample and across disease severity levels.
Sample and model type N Mean ME MAE RMSE
Full sample
Linear 1615 0.5732 0.0056 0.1621 0.2122
Indirect 1615 0.5691 0.0092 0.1591 0.2101
Direct 3 class 1615 0.5792 –0.0004 0.1581 0.2104
Direct 4 class 1615 0.5791 –0.0003 0.1578 0.2102
Observed 1615 0.5788
BASDAI/100 quartiles 75–100 (r0.62 to 1)
Linear 404 0.3071 –0.0179 0.2471 0.2753
Indirect 0.2638 0.0265 0.2414 0.2743
Direct 3 class 0.2772 0.0120 0.2417 0.2734
Direct 4 class 0.2770 0.0122 0.2411 0.2729
Observed 0.2892
50–75 (r0.429 to o0.62)
Linear 405 0.5217 –0.0057 0.1841 0.2403
Indirect 0.5145 –0.0032 0.1851 0.2392
Direct 3 class 0.5283 –0.0124 0.1831 0.2421
Direct 4 class 0.5296 –0.0136 0.1825 0.2419
Observed 0.5159
25–50 (r0.213 to o0.429)
Linear 402 0.6763 0.0085 0.1063 0.1613
Indirect 0.6787 0.0080 0.1034 0.1596
Direct 3 class 0.6869 –0.0021 0.1021 0.1603
Direct 4 class 0.6858 –0.0009 0.1023 0.1602
Observed 0.6848
0–25 (0 to o0.213)
Linear 404 0.7885 0.0374 0.1107 0.1428
Indirect 0.8200 0.0056 0.1064 0.1361
Direct 3 class 0.8250 0.0010 0.1051 0.1340
Direct 4 class 0.8248 0.0011 0.1050 0.1338
Observed 0.8259
BASFI/100 quartiles 75–100 (o0.62 to 1)
Linear 400 0.3108 –0.0134 0.2409 0.2713
Indirect 0.2825 0.0194 0.2341 0.2697
Direct 3 class 0.2969 0.0004 0.2328 0.2708
Direct 4 class 0.2966 0.0007 0.2327 0.2706
Observed 0.2973
50–75 (0.429 r 0.62)
Linear 408 0.5083 –0.0061 0.1839 0.2369
Indirect 0.4959 0.0022 0.1847 0.2363
Direct 3 class 0.5086 –0.0063 0.1869 0.2384
Direct 4 class 0.5088 –0.0065 0.1863 0.2381
Observed 0.5023
25–50 (0.213 r 0.429)
Linear 404 0.6829 0.0224 0.1195 0.1680
Indirect 0.6863 0.0171 0.1167 0.1654
Direct 3 class 0.6924 0.0129 0.1137 0.1630
Direct 4 class 0.6922 0.0131 0.1134 0.1626
Observed 0.7053
0–25 (0 Z 0.213)
Linear 403 0.7894 0.0194 0.1047 0.1490
Indirect 0.8102 –0.0017 0.1014 0.1438
Direct 3 class 0.8174 –0.0085 0.0992 0.1430
Direct 4 class 0.8175 –0.0086 0.0992 0.1430
Observed 0.8088
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; MAE, mean absolute error;
ME, mean error; RMSE, root mean square error.
Note: Bold, italicized numbers indicate closest ﬁt to observed data.
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The mean estimated by the mixture models is very close to the
observed mean from the data. The indirect method has the
lowest RMSE but performs worst in terms of the estimated mean
and the mean error.Plots of the estimated means compared with the mean
observed data across the range of BASFI and BASDAI are shown
in Figure 1A and Figure 1B, respectively. The linear model shows
characteristic underestimation of the EQ-5D value at low levels of
disease in both plots. At high levels of BASDAI, the model
Fig. 1 – Mean EQ-5D vs (A) BASDAI and (B) BASFI for observed versus estimated. BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; EQ-5D, EuroQol ﬁve-dimensional questionnaire.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 2 5 – 4 3 1 429overestimates the EQ-5D value. When plotted against BASFI, this
overestimation is not apparent.
The mixture model approaches ﬁt very closely to the observed
means across the entire range of disease and do not exhibit the
bias of the linear regression model. Mean ﬁt at the extremes of
the distribution of disease severity is also improved by the
indirect approach compared with the linear model. It is at the
midrange of disease severity where mean ﬁt is marginally less
accurate for the indirect approach than for the direct approach.
Fit across the range of disease severity is further explored in
Table 3 and shows a similar pattern to that observed for the
aggregate data. Subsets are deﬁned by quartiles of BASDAI/100
and BASFI/100. For most measures, the three- and four-class
direct mixture model approaches outperform the linear and
indirect approaches. This is not universal across all measures
or all disease severity subsets, and the magnitude of differences
between methods also varies.
The difference between the estimated mean for each model-
ing approach and the observed mean is greatest at the extremes
of the distribution. The linear model underestimates the mean
EQ-5D value for the lower BASDAI/100 quartile (between 0 andTable 3 – Observed compared with simulated data sets.
Observed Linear
Mean 0.579 0.560
Variance 0.098 0.088
Skewness 0.991 0.155
Kurtosis 3.127 2.960
Minimum 0.594 0.746
Maximum 1.000 1.912
Percentiles
1% 0.184 0.160
5% 0.016 0.054
10% 0.003 0.170
25% 0.516 0.363
50% 0.689 0.570
75% 0.796 0.765
90% 0.883 0.935
95% 1.000 1.033
99% 1.000 1.213
3LC, 3 Latent-component; 4LC, 4 Latent-component.
Note: Closest ﬁt to observed data in bold.0.213) by 0.04 and overestimates for the upper BASDAI/100
quartile (between 0.62 and 1) by 0.02. For the latter category, the
indirect approach underestimates the mean EQ-5D value by 0.03.
The indirect approach ﬁts very closely to the data in terms of
estimated mean, mean error, and RMSE for the next BASDAI/100
quartile (0.43–0.62).
The estimated change in the mean EQ-5D value associated
with moving from the lowest to the highest BASDAI quartile is
0.481, 0.556, 0.548, and 0.548 for the linear, indirect, three-
component, and four-component mixture models, respectively.
This is a difference of 0.08 between the methods. The difference
in the observed data is 0.537.
The estimated change in the mean EQ-5D value associated
with moving from the lowest to the highest BASFI quartile is
0.479, 0.528, 0.520, and 0.521 for the linear, indirect, three-
component, and four-component mixture models, respectively.
This is a difference of 0.05 between the methods. The difference
in the observed data is 0.511.
Comparisons to this point are based on comparing predicted
values from the different estimated models with the original
data. These kinds of measures are of most importance for those3LC 4LC Indirect
0.580 0.579 0.569
0.097 0.097 0.091
0.978 0.979 0.917
3.089 3.103 2.829
0.593 0.594 0.594
1.000 1.000 1.000
0.187 0.201 0.181
0.062 0.041 0.016
0.024 0.024 0.055
0.519 0.519 0.516
0.662 0.662 0.689
0.769 0.768 0.760
1.000 1.000 0.848
1.000 1.000 1.000
1.000 1.000 1.000
F
E
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conditional on appropriate covariates. This would be of particular
relevance to those interested in using these approaches to
populate a standard cohort–based cost-effectiveness model, for
example. For those settings in which simulated data incorporat-
ing individual-level variability must be reﬂected, such as in a true
patient-level simulation model or in imputing missing
individual-level patient data, for example, from a clinical trial,
additional performance criteria are relevant. Table 3 provides
details of the distribution of EQ-5D values in the original data set
and compares this with the distribution of simulated data for
each of the 1615 patients, replicated 1000 times to ensure
sampling error is minimized, from each of the four models.
These simulations are produced by incorporating not only the
age, BASFI, and BASDAI for each patient but also the random
error term(s) for each statistical model. Note that this is a quite
different comparison from those based on predicted values
reported earlier. Figure 2 supplements with plots of the ﬁve
distributions on identical scales.
The data simulated using the linear regression bear little
resemblance to the distribution of the original data, though the
mean and variance are accurate in broad terms. Importantly, the
model simulates data outside the range of feasible values both
above full health (maximum of 1.9) and below (minimum of 0.7).
The mixture model and indirect approaches closely resemble the
distribution of original data. They each simulate values up to the
extremes of the feasible range, but they cannot generate values
outside this. Summary statistics shown in the upper part of
Table 3 indicate that the four-class model is almost identical to
the observed data. Figure 2 illustrates that the “lumpy” nature of
the original data is better replicated by the indirect approach
because this generates the 243 discrete values of the EQ-5D,
whereas the mixture models treat most of the distribution as
continuous. Despite this feature, however, there are some clear
differences between the indirect approach and the observed data.
For example, the proportion of observations at 1 is clearlyig. 2 – Plots of observed and simulated data from linear, three a
uroQol ﬁve-dimensional questionnaire; 3LC, 3 Latent-componenunderrepresented. Both the three- and four-class mixture models
reﬂect the key characteristics of the EQ-5D distribution such as
the mass of observations at 1, the gap in values between 1 and
0.883, and the trimodal distribution.Discussion
Approaches to statistical modeling of preference-based outcome
measures, such as the EQ-5D, have been largely simplistic to
date, though there has been substantial investigation of alter-
native methods in recent years. The linear regression approach is
theoretically ill-suited to modeling data with characteristics of
the EQ-5D, yet it has obvious appeal because it is straightforward
to estimate and interpret. In AS, all published assessments we
are aware of have used linear regression models.
This article compared the linear regression approach to two
alternative methods that have both theoretical appeal and a
degree of empirical evidence to support their use: direct modeling
using bespoke mixtures and an indirect approach using general-
ized ordered probit models. Results show the bias associated with
the linear model that is now well documented [17,19] and the
ability of both alternative methods to overcome this bias. This is
a potentially substantial bias that can be masked to some degree
by the use of measures such as the RMSE and mean absolute
error and the limited utility scale. When one considers the use of
mapping functions in transition state cohort models, a difference
of 0.08 between values that could be applied to health states
according to the method clearly has potential to substantially
alter estimates of cost-effectiveness substantially. To provide
context to this difference, Ara et al. [9] report estimated differ-
ences in utilities between patients treated with etanercept plus
steroids versus steroids alone for each of 25 years. The largest
difference in any year was 0.23. Analysts should be wary of
dismissing apparently small differences in the RMSE and the
mean absolute error, which were developed in the very differentnd four latent class models, and indirect approach. EQ-5D,
t; 4LC, 4 Latent-component.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 2 5 – 4 3 1 431context of statistical forecasting, when applied to mapping,
which has a very limited range for the health utility scale.
Exactly how these differences translate into differences in
cost-effectiveness will be highly situation speciﬁc, depending on
the magnitude and nature of the treatment effect, the use of
cohort or patient-level decision models, and whether the EQ-5D is
treated as a continuous variable in the cost-effectiveness analysis
and, if not, the degree of “lumpiness” in the categories used.
We demonstrate the further inappropriateness of the linear
model for generating simulated data: it generates values outside
the feasible range and cannot mimic any of the key features of
the distribution of the actual data. It should be noted, however,
that the mean and variance do approximate that observed in the
data when the error distribution of the model is properly
incorporated. The suitability of both the mixture model and
indirect approaches is demonstrated by the very close relation-
ship between simulated data and the observed patient values,
including its variance. In particular, the four-class mixture model
produces a distribution that has near identical summary statis-
tics to those observed in the original patient data.
In the broader mapping literature there is a tendency to use
two data sets: one for “estimation” and one for “validation.” We
provide no such analysis. Models should be estimated in data sets
appropriate for the decision problem to which they are to be
applied: in this case, our data set spans the entire range of disease
and is thus relevant to all potential decision problems. If a model
is estimated on one data set and then applied in a second data set
with equivalent characteristics, then equivalent results will be
observed. If results differ, it is because the data sets differ.
Validation data sets can validate neither methods nor results but
provide a weak test of the appropriateness of the original data set.
Overall, we conclude that the mixture model approach pro-
vides the best performing model for estimating the EQ-5D value
from BASDAI and BASFI. We provide an excel calculator as an
Appendix in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2015.02.016 to allow interested users to easily gen-
erate estimates for their own data sets for both three- and four-
component variants.
Our conclusions are based on a large data set that spans the
entire range of disease severity. We ﬁnd that age has a statistically
signiﬁcant and positive effect on the EQ-5D, in all the model types,
after controlling for functional health impairment. This is consistent
with ﬁndings in other disease areas [17]. This natural effect of aging
ought to be reﬂected by analysts when estimating cost-effectiveness
to avoid misappropriating beneﬁt to a particular treatment.
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